Dupilumab: A Review of Present Indications and Off-Label Uses

• Published in: Journal of investigational allergology & clinical immunology Vol. 32; no. 2; pp. 97 - 115
• Main Authors: Muñoz-Bellido, F J, Moreno, E, Dávila, I
• Format: Journal Article
• Language: English
• Published: Spain Esmon Publicidad 01.01.2022
• Subjects: Allergic bronchopulmonary aspergillosis; Allergic rhinitis; Alopecia; Antibodies, Monoclonal, Humanized - therapeutic use; Aspergillosis; Bullous pemphigoid; Clinical trials; Contact dermatitis; Eczema; Eczema - drug therapy; Esophagitis; Food allergies; Gastrointestinal diseases; Humans; Inflammation; Interleukin 13; Interleukin 4; Leukocytes (eosinophilic); Monoclonal antibodies; Netherton syndrome; Off-Label Use; Respiratory diseases; Skin diseases; Urticaria; Food allergy; Allergic contact dermatitis; Cutaneous autoimmune bullous diseases; Eosinophilic esophagitis; Allergic bronchopulmonary aspergillosis; Chronic urticaria; Dupilumab; Alopecia areata
• ISSN: 1018-9068; 1698-0808
• DOI: 10.18176/jiaci.0682

Recent advances in our understanding of T2 inflammation have revealed more diseases in which T2 inflammation is involved. Dupilumab is a recently developed monoclonal antibody that blocks signaling of IL-4 and IL-13, both of which are crucial cytokines in the T2 response. New possible indications are increasingly explored and include skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, as well as respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy, are also research fields of interest. Here, we review published data and clinical trials examining the use of dupilumab in these disorders.